March 17, 2023
Access & Coverage | Tea Leaves
  • French pharmaceutical company Sanofi, one of the top three insulin manufacturers for the U.S., announced on Thursday it would be cutting the list price for its most prescribed insulin product, Lantus, by 78 percent, joining fellow major insulin manufacturers in drastically minimizing the prices of some of their insulin products. The company also said it would be reducing the cost of its fast-acting insulin product, Apidra, by 70 percent and enacting a $35 cap on out-of-pocket costs for Lantus for patients with commercial insurance coverage as well as capping costs for uninsured patients through its various savings programs. (Articles here, here, here, and here)